Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): A systematic review - 16/02/16
Abstract |
Background |
Current knowledge of angiolymphoid hyperplasia with eosinophilia (ALHE) derives from retrospective reports and case series, leading to a nonevidence-based treatment approach.
Objective |
We sought to systematically review the literature relating to cutaneous ALHE to estimate its epidemiology and treatment outcomes.
Methods |
A literature search of PubMed, EMBASE, Web of Science, and Google Scholar was conducted. Articles detailing cases of histologically confirmed cutaneous ALHE were included.
Results |
In all, 416 studies were included in the review, representing 908 patients. There was no sex predominance among patients with ALHE. Mean age at presentation was 37.6 years. There was a significant association between presence of multiple lesions and pruritus, along with bleeding. Surgical excision was the most commonly reported treatment for ALHE. Treatment failure was lowest for excision and pulsed dye laser. Mean disease-free survival after excision was 4.2 years. There were higher rates of recurrence postexcision with earlier age of onset, longer duration of disease, multiple lesions, bilateral lesions, pruritus, pain, and bleeding.
Limitations |
Potential for publication bias is a limitation.
Conclusions |
Surgical excision appears to be the most effective treatment for ALHE, albeit suboptimal. Pulsed dye and other lasers may be effective treatment options. More studies are needed to improve the treatment of ALHE.
Le texte complet de cet article est disponible en PDF.Key words : angiolymphoid hyperplasia with eosinophilia, epidemiology, excision, histiocytoid hemangioma, pseudopyogenic granuloma, surgery
Plan
Drs Adler and Krausz contributed equally to this work. |
|
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 74 - N° 3
P. 506 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?